Omeprazole

Generic Name: Omeprazole

Brand Names: Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₃O_₃S

CAS Number: 73590-58-6

Unique Ingredient Identifier: KG60484QX9

Background: Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...

Indication: Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:

• Treatment of active duodenal ulcer in adults

• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults

• Treatment of active benign gastric ulcer in adults
...

Associated Conditions: Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas

Associated Therapies: -

Clinical Trials

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Tralokinumab
Drug: Caffeine
Drug: Warfarin
Drug: Omeprazole
Drug: Metoprolol
Drug: Midazolam Hydrochloride

First Posted Date: 2018-06-14

Last Posted Date: 2024-10-26

Lead Sponsor: LEO Pharma

Target Recruit Count: 40

Registration Number: NCT03556592

Locations: 🇳🇱
LEO Pharma Investigational Site, Leiden, Netherlands

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tepotinib
Drug: Omeprazole

First Posted Date: 2018-05-22

Last Posted Date: 2023-07-28

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 12

Registration Number: NCT03531762

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Phase 1

Completed

Conditions: Drug-drug Interaction
Autoimmune Diseases
Fibrotic Disease

Interventions: Drug: Belumosudil
Drug: Itraconazole
Drug: Rabeprazole
Drug: Rifampicin
Drug: Omeprazole

First Posted Date: 2018-05-21

Last Posted Date: 2022-05-25

Lead Sponsor: Kadmon Corporation, LLC

Target Recruit Count: 73

Registration Number: NCT03530995

Locations: 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam hydrochloride
Drug: Metoprolol tartrate
Drug: Pioglitazone hydrochloride
Drug: Tolbutamide
Drug: Omeprazole
Drug: Relacorilant

First Posted Date: 2018-03-07

Last Posted Date: 2018-05-17

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 27

Registration Number: NCT03457597

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Danirixin
Drug: Omeprazole

First Posted Date: 2018-03-07

Last Posted Date: 2021-05-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT03457727

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Single Dose Omeprazole Versus High Dose in High-risk Critically Ill Patients.

Not Applicable

Completed

Conditions: Critical Illness

Interventions: Drug: Placebo group
Drug: Omeprazole

First Posted Date: 2018-01-03

Last Posted Date: 2018-01-03

Lead Sponsor: Menoufia University

Target Recruit Count: 110

Registration Number: NCT03388463

Efficacy and Safety of DLBS2411 in the Management of GERD

Phase 3

Terminated

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: DLBS2411
Drug: Omeprazole
Drug: Placebo capsule of Omeprazole
Drug: Placebo caplet of DLBS2411

First Posted Date: 2017-12-08

Last Posted Date: 2021-01-07

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 32

Registration Number: NCT03367195

Locations: 🇮🇩
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital, Bandung, Indonesia
🇮🇩
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital, Semarang, Indonesia
🇮🇩
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Airlangga Dr. Soetomo Hospital, Surabaya, Indonesia

and more 2 locations